Responsible for the company’s development portfolio, including responsibility for prioritizing and accelerating the development of PhaseBio’s drug candidates. • Partners with CEO and CFO to provide strategic leadership to the scientific, clinical, and business teams, and drives strategic planning, partnering discussions, and presentations to investors and the Board of Directors.• Works to develop, lead, and drive the research and discovery as well as lead clinical development and regulatory strategy of PhaseBio’s pipeline

Responsible for development and implementation of the CV therapeutic area business growth strategy at Quintiles. The Global Head of the CV COE represents Quintiles’ CV therapeutic expertise across the broader Enterprise and in the global marketplace• Led development of optimal strategies for CV drug development, product lifecycle management, and portfolio management for our customers • Built partnerships/alliances with external organizations to enable accelerated and innovative drug development and clinical research• Provided medical, clinical, scientific, regulatory and drug R&D advisory expertise in CV drug development across the Quintiles enterprise

Head of CV/Metabolic Discovery Medicine and Clinical BiomarkersExploratory Clinical and Translational ResearchCo-Chair CV Translational R&D Core TeamEarly Development Team Leader - Atherosclerosis, HypercholesterolemiaClinical Lead experience - Atherosclerosis, Thrombosis, Arrhythmia, Heart Failure

Medical Affairs, Medical Information, and Medical-Legal Board support of Atherosclerosis, Arrhythmia, and Heart Failure products

Principal Investigator, NIH/NHLBI K08 HL081084: LKLF and vascular responses to hemodynamic shear in vivo.Division of Cardiovascular Medicine, University of Pennsylvania